8% of All US Prescriptions Are Now GLP-1s: What That Means

A number like "8%" doesn't sound dramatic until you realize what it represents: nearly 8 out of every 100 prescriptions written in the United States are now for GLP-1 receptor agonists. According to Truveta's analysis of more than 130 million electronic health records, this milestone was reached in March 2026 — and it represents the single largest quarter-over-quarter percentage point increase since tracking began in 2019.

The Growth Trajectory

To understand how fast this happened, consider the timeline. In September 2025, GLP-1s accounted for roughly 6.5% of all US prescriptions. By December 2025, that number had crossed 7%. Then between December 2025 and March 2026, overall GLP-1 prescribing surged another 15%, pushing it to nearly 8% — a gain of more than one full percentage point in a single quarter.

That jump was overwhelmingly driven by anti-obesity medication (AOM) use, not diabetes. First-time AOM prescriptions climbed 21.7% in the same three-month window. First-time anti-diabetic GLP-1 prescriptions actually declined by 9.8%. The narrative has flipped: GLP-1s are now primarily an obesity treatment that also happens to treat diabetes, not the other way around.

What Caused the Spike?

Several forces converged in late 2025 and early 2026:

Oral Wegovy approval. The FDA approved oral semaglutide for obesity in late 2025, removing the injection barrier that kept millions of potential patients on the sidelines. First-time AOM semaglutide prescribing jumped more than 50% in Q1 2026 alone — its largest quarterly increase ever. For people who wanted GLP-1 benefits but couldn't stomach a weekly injection, the pill changed the calculation entirely.

Expanded insurance coverage. The Medicare $50/month GLP-1 copay program, scheduled to launch July 1, 2026, was announced in early 2026. Even before it took effect, the announcement signaled to prescribers and patients that coverage barriers were falling. Several private insurers followed with expanded formulary inclusion.

Supply recovery. Eli Lilly announced at the January 2026 J.P. Morgan Healthcare Conference that its manufacturing bottlenecks were resolved. Novo Nordisk had similarly ramped production. For the first time since the GLP-1 boom began, supply could plausibly meet demand.

Clinical evidence accumulation. SURMOUNT-5 confirmed tirzepatide's superiority over semaglutide. The FLOW trial showed kidney protection. STEP-HFpEF demonstrated heart failure benefits. Each new study expanded the clinical justification for prescribing.

The Dispensing Gap Problem

There's a critical number buried in the Truveta data that gets far less attention: only 46.8% of first-time anti-obesity GLP-1 prescriptions result in a fill within 60 days. Compare that to 72.2% for anti-diabetic GLP-1 prescriptions. More than half of people who get a prescription for obesity never actually pick up the medication.

The reasons are predictable: cost, insurance denials, prior authorization delays, and pharmacy-level supply issues. This dispensing gap means the 8% figure actually understates demand. If every written prescription were filled, GLP-1 market share would be substantially higher.

This is also part of why real-world GLP-1 outcomes lag clinical trial results — patients who never fill their prescriptions obviously don't lose weight, but they still count in population-level analyses.

Tirzepatide Is Winning the Market Share War

Within the GLP-1 class, tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) has become the most prescribed GLP-1 for both indications. It showed the largest increase in total prescribing from September to December 2025, a trend that accelerated into Q1 2026.

This tracks with both clinical data and pricing. SURMOUNT-5 established tirzepatide's superiority for weight loss. Meanwhile, Eli Lilly's LillyDirect program offers Zepbound at $399/month for cash-pay patients — substantially below Wegovy's list price of roughly $1,349/month.

What 8% Means for the Healthcare System

When a single drug class captures nearly one in twelve prescriptions nationwide, the downstream effects are enormous:

Pharmacy economics. GLP-1s are among the most expensive prescription categories. When they represent 8% of prescription volume but a far larger share of prescription spending, pharmacy benefit managers and insurers have to restructure entire formularies around them.

Manufacturing scale. The pharmaceutical industry is investing tens of billions in GLP-1 production capacity. Eli Lilly alone has committed $27 billion to new US manufacturing facilities, at least three of which are dedicated to weight loss therapies including the upcoming oral medication orforglipron.

Regulatory pressure. The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is directly connected to this growth. When compounded versions reach roughly 30% of supply — as they did at peak in 2024 — the regulatory stakes become enormous. The June 30 comment deadline is the next inflection point.

Broader health outcomes. If the obesity-driven growth continues — and there's no sign it won't — GLP-1s could reach 10% of all prescriptions by late 2026 or early 2027. At that scale, population-level effects on cardiovascular disease, type 2 diabetes incidence, kidney disease, and even certain cancers could begin showing up in national health statistics.

What This Means for Patients

For people considering GLP-1 therapy, the market shift creates both opportunities and challenges. More providers, more formulations (including oral options), and more insurance coverage pathways exist now than at any point in the past. At the same time, the regulatory landscape is tightening around compounded options, pricing remains high for uninsured patients, and the sheer volume of new prescribers means quality of medical oversight varies widely.

The dispensing gap data also suggests that getting a prescription is only half the battle. Finding affordable access to actually fill it — through insurance, manufacturer programs, or legitimate compounding while it remains available — is where most patients hit real friction.

Sources

• Truveta Research, "GLP-1 RA prescription trends through March 2026," April 2026. 130M+ US patient EHR dataset.
• Drug Topics, "GLP-1s Made Up Eight Of Every 100 Prescriptions Filled in March 2026," May 2026.
• Truveta Research, "GLP-1 RA prescription trends: January 2019 – December 2025," January 2026.
• Eli Lilly 8-K filing, Q4 2025 earnings and 2026 guidance, February 4, 2026.